Cargando…

Outpatient administration of naxitamab in combination with granulocyte‐macrophage colony‐stimulating factor in patients with refractory and/or relapsed high‐risk neuroblastoma: Management of adverse events

BACKGROUND: Naxitamab is a humanized GD2‐binding monoclonal antibody that received accelerated approval from the U.S. Food and Drug Administration for refractory or relapsed high‐risk neuroblastoma limited to bone or bone marrow. Trial 201 (NCT03363373) is an ongoing global clinical trial to evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mora, Jaume, Chan, Godfrey C., Morgenstern, Daniel A., Nysom, Karsten, Bear, Melissa K., Tornøe, Karen, Kushner, Brian H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875606/ https://www.ncbi.nlm.nih.gov/pubmed/35579862 http://dx.doi.org/10.1002/cnr2.1627

Ejemplares similares

Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report
por: Mora, Jaume, et al.
Publicado: (2023)

Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine
por: Galassi, Lucrezia, et al.
Publicado: (2023)

Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab
por: Varo, Amalia, et al.
Publicado: (2023)

Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
por: Muñoz, Juan Pablo, et al.
Publicado: (2023)

How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain
por: Castañeda, A., et al.
Publicado: (2022)

Novel Therapies for Relapsed and Refractory Neuroblastoma
por: Zage, Peter E.
Publicado: (2018)

Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
por: Mora, Jaume, et al.
Publicado: (2021)

Corrigendum to “How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain”: [ESMO Open, 7 (2022) 100462]
por: Castañeda, A., et al.
Publicado: (2022)

Non-Articular Felty Syndrome Refractory to Granulocyte Colony-Stimulating Factor Therapy
por: Saeed, Hasham, et al.
Publicado: (2021)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Cladribine with Granulocyte Colony‐Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study
por: Wang, Hua, et al.
Publicado: (2020)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004)

Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases
por: Okada, Keiko, et al.
Publicado: (2016)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022)

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
por: Suk, Yujin, et al.
Publicado: (2023)

Treating Relapsed/Refractory Acute Myeloid Leukemia with Chidamide, Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor with Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
por: Yao, Wen, et al.
Publicado: (2022)

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
por: Goldsmith, Kelly C., et al.
Publicado: (2023)

Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)

Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma
por: Saulnier Sholler, Giselle L, et al.
Publicado: (2015)

Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study
por: Wang, Lixin, et al.
Publicado: (2020)

Granulocyte Colony-Stimulating Factor in Amniotic Fluid
por: Raynor, B. Denise, et al.
Publicado: (1995)

The importance of the granulocyte-colony stimulating factor in oncology
por: CETEAN, SÎNZIANA, et al.
Publicado: (2015)

Granulocyte Colony-stimulating Factor-associated Aortitis
por: Nishioka, Hiroaki, et al.
Publicado: (2023)

In vitro Colony Forming Cells and Colony Stimulating Factor in Chronic Granulocytic Leukaemia
por: Goldman, J. M., et al.
Publicado: (1974)

Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma
por: Liévin, Raphaël, et al.
Publicado: (2022)

Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis
por: Bo, Lulong, et al.
Publicado: (2011)

In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients.
por: Bronchud, M. H., et al.
Publicado: (1988)

Granulocyte-colony stimulating factor producing rectal cancer
por: Takahashi, Hiroki, et al.
Publicado: (2008)

Serum Granulocyte Colony-Stimulating Factor and Alzheimer's Disease
por: Barber, Robert C., et al.
Publicado: (2012)

Role of granulocyte colony-stimulating factor in human reproduction
por: Eftekhar, Maryam, et al.
Publicado: (2018)

Migratory Aortitis Associated with Granulocyte-colony-stimulating Factor
por: Shirai, Tsuyoshi, et al.
Publicado: (2020)

Granulocyte Colony-Stimulating Factor-Producing Bladder Cancer
por: Morinaga, Ryota, et al.
Publicado: (2019)

Granulocyte colony‐stimulating factor producing retroperitoneal leiomyosarcoma
por: Fukuta, Kyotaro, et al.
Publicado: (2020)

Granulocyte colony‐stimulating factor is not pathogenic in lupus nephritis
por: Gottschalk, Timothy A., et al.
Publicado: (2021)

Thrombin Stimulates Synthesis of Macrophage Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulating Factor by Human Proximal Tubular Epithelial Cells in Culture
por: Shimaya, Yuko, et al.
Publicado: (2012)

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
por: Song, Ga-Young, et al.
Publicado: (2023)

Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial
por: Loeb, David M., et al.
Publicado: (2022)

Whole lung lavage combined with Granulocyte-macrophage colony stimulating factor inhalation for an adult case of refractory pulmonary alveolar proteinosis
por: Yu, Hong yan, et al.
Publicado: (2014)

Combined application of alginate dressing and human granulocyte-macrophage colony stimulating factor promotes healing in refractory chronic skin ulcers
por: HUANG, GUOBAO, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_uvcei4vk7uhf4pqht7k6heati5